Trial Outcomes & Findings for A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions. (NCT NCT04550936)

Last Updated: 2025-12-09

Results Overview

Mycological response was evaluated according to the following mutually exclusive modalities: Mycological success, mycological failure and unknown. Mycological success: eradication or presumed eradication of the original causative organism cultured. Mycological failure: persistence or presumed persistence. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any mycological response at Week 12 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Recruitment status

COMPLETED

Target enrollment

307 participants

Primary outcome timeframe

Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Results posted on

2025-12-09

Participant Flow

Data from the medical records of participants with invasive aspergillosis or mucormycosis who initiated isavuconazole treatment during the index period of 15 October 2015 until 30 June 2019 were included in this study.

Retrospective data was extracted and evaluated from study start date and until study completion (approximately 34 months) of this retrospective observational study. Participants were followed from index date until 6 months post-index treatment discontinuation, death, loss to follow-up, whichever occurs first.

Participant milestones

Participant milestones
Measure	Invasive Aspergillosis Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Overall Study STARTED	201	17
Overall Study COMPLETED	201	17
Overall Study NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Total n=218 Participants Total of all reporting groups
Age, Continuous	56.0 Years STANDARD_DEVIATION 15.6 • n=201 Participants	66.5 Years STANDARD_DEVIATION 12.8 • n=17 Participants	56.8 Years STANDARD_DEVIATION 15.6 • n=218 Participants
Sex: Female, Male Female	65 Participants n=201 Participants	9 Participants n=17 Participants	74 Participants n=218 Participants
Sex: Female, Male Male	136 Participants n=201 Participants	8 Participants n=17 Participants	144 Participants n=218 Participants
Race and Ethnicity Not Collected	—	—	0 Participants Race and Ethnicity were not collected from any participant.

PRIMARY outcome

Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Clinical response was evaluated according to the following mutually exclusive modalities: Clinical success, clinical failure and unknown. Clinical success: resolution or partial resolution of all attributable clinical symptoms and physical findings. Clinical failure: no resolution of any attributable clinical symptoms and physical findings and/or worsening. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any clinical response at Week 6 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Clinical Response at Week 6 Unknown	173 Participants	14 Participants
Number of Participants With Clinical Response at Week 6 Clinical success	27 Participants	3 Participants
Number of Participants With Clinical Response at Week 6 Clinical failure	1 Participants	0 Participants

PRIMARY outcome

Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Clinical response was evaluated according to the following mutually exclusive modalities: Clinical success, clinical failure and unknown. Clinical success: resolution or partial resolution of all attributable clinical symptoms and physical findings. Clinical failure: no resolution of any attributable clinical symptoms and physical findings and/or worsening. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any clinical response at Week 12 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Clinical Response at Week 12 Clinical failure	0 Participants	0 Participants
Number of Participants With Clinical Response at Week 12 Unknown	185 Participants	15 Participants
Number of Participants With Clinical Response at Week 12 Clinical success	16 Participants	2 Participants

PRIMARY outcome

Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Clinical response was evaluated according to the following mutually exclusive modalities: Clinical success, clinical failure and unknown. Clinical success: resolution or partial resolution of all attributable clinical symptoms and physical findings. Clinical failure: no resolution of any attributable clinical symptoms and physical findings and/or worsening. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any clinical response at Week 24 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Clinical Response at Week 24 Unknown	193 Participants	17 Participants
Number of Participants With Clinical Response at Week 24 Clinical success	8 Participants	0 Participants
Number of Participants With Clinical Response at Week 24 Clinical failure	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Week 6 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Radiological response was evaluated according to the following mutually exclusive modalities: Radiological success, radiological failure and unknown. Radiological success: greater than or equal to (\>=) 50 percent (%) improvement from initial assessment, or improvement of at least 25% from the initial assessment for the follow-up at 6 weeks or if end of treatment occurred before this time. Radiological failure: Failure to meet success criteria. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any radiological response at Week 6 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Radiological Response at Week 6 Unknown	188 Participants	14 Participants
Number of Participants With Radiological Response at Week 6 Radiological success	11 Participants	3 Participants
Number of Participants With Radiological Response at Week 6 Radiological failure	2 Participants	0 Participants

PRIMARY outcome

Timeframe: Week 12 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Radiological response was evaluated according to the following mutually exclusive modalities: Radiological success, radiological failure and unknown. Radiological success: \>= 50% improvement from initial assessment, or improvement of at least 25% from the initial assessment for the follow-up at 12 weeks or if end of treatment occurred before this time. Radiological failure: Failure to meet success criteria. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any radiological response at Week 12 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Radiological Response at Week 12 Radiological success	9 Participants	1 Participants
Number of Participants With Radiological Response at Week 12 Unknown	190 Participants	16 Participants
Number of Participants With Radiological Response at Week 12 Radiological failure	2 Participants	0 Participants

PRIMARY outcome

Timeframe: Week 24 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Radiological response was evaluated according to the following mutually exclusive modalities: Radiological success, radiological failure and unknown. Radiological success: \>= 50% improvement from initial assessment, or improvement of at least 25% from the initial assessment for the follow-up at 24 weeks or if end of treatment occurred before this time. Radiological failure: Failure to meet success criteria. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any radiological response at Week 24 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Radiological Response at Week 24 Unknown	195 Participants	16 Participants
Number of Participants With Radiological Response at Week 24 Radiological success	4 Participants	0 Participants
Number of Participants With Radiological Response at Week 24 Radiological failure	2 Participants	1 Participants

PRIMARY outcome

Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Mycological response was evaluated according to the following mutually exclusive modalities: Mycological success, mycological failure and unknown. Mycological success: eradication or presumed eradication of the original causative organism cultured. Mycological failure: persistence or presumed persistence. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any mycological response at Week 6 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Mycological Response at Week 6 Unknown	190 Participants	17 Participants
Number of Participants With Mycological Response at Week 6 Mycological Success: Presumed eradication	7 Participants	0 Participants
Number of Participants With Mycological Response at Week 6 Mycological Success: Eradication	4 Participants	0 Participants
Number of Participants With Mycological Response at Week 6 Mycological Failure	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Mycological Response at Week 12 Unknown	195 Participants	17 Participants
Number of Participants With Mycological Response at Week 12 Mycological Success: Presumed eradication	3 Participants	0 Participants
Number of Participants With Mycological Response at Week 12 Mycological Success: Eradication	3 Participants	0 Participants
Number of Participants With Mycological Response at Week 12 Mycological Failure	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Mycological response was evaluated according to the following mutually exclusive modalities: Mycological success, mycological failure and unknown. Mycological success: eradication or presumed eradication of the original causative organism cultured. Mycological failure: persistence or presumed persistence. Unknown: if there was not enough documentation to make the classification success or failure. Number of participants with any mycological response at Week 24 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Mycological Response at Week 24 Unknown	198 Participants	17 Participants
Number of Participants With Mycological Response at Week 24 Mycological Success: Presumed eradication	1 Participants	0 Participants
Number of Participants With Mycological Response at Week 24 Mycological Success: Eradication	0 Participants	0 Participants
Number of Participants With Mycological Response at Week 24 Mycological Failure	2 Participants	0 Participants

PRIMARY outcome

Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants who died due to any cause at Week 6 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
All-Cause Mortality at Week 6	48 Participants	1 Participants

PRIMARY outcome

Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants who died due to any cause at Week 12 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
All-Cause Mortality at Week 12	74 Participants	2 Participants

PRIMARY outcome

Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants who died due to any cause at Week 24 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
All-Cause Mortality at Week 24	93 Participants	5 Participants

PRIMARY outcome

Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Number of participants with any adverse event based on the medical records at Week 6 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Adverse Event at Week 6	33 Participants	2 Participants

PRIMARY outcome

Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Number of participants with any adverse event based on the medical records at Week 12 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Adverse Event at Week 12	38 Participants	3 Participants

PRIMARY outcome

Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Number of participants with any adverse event based on the medical records at Week 24 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Adverse Event at Week 24	42 Participants	3 Participants

PRIMARY outcome

Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Serious adverse event = any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, or resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect. Number of participants with any serious adverse event based on the medical records at Week 6 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Serious Adverse Event at Week 6	26 Participants	2 Participants

PRIMARY outcome

Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Serious adverse event = any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, or resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect. Number of participants with any serious adverse event based on the medical records at Week 12 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Serious Adverse Event at Week 12	30 Participants	3 Participants

PRIMARY outcome

Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Serious adverse event = any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, or resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect. Number of participants with any serious adverse event based on the medical records at Week 24 post index date were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Serious Adverse Event at Week 24	34 Participants	3 Participants

SECONDARY outcome

Timeframe: At index date (date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019); retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants according to method of drug administration: infusion, oral and unknown were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants According to Method of Administration Infusion	105 Participants	8 Participants
Number of Participants According to Method of Administration Oral	92 Participants	9 Participants
Number of Participants According to Method of Administration Unknown	4 Participants	0 Participants

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants according to dosage of drug administration: 200 milligram (mg), other and unknown were reported in this outcome measure.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants According to Dosage of Isavuconazole Administration 200 mg	186 Participants	17 Participants
Number of Participants According to Dosage of Isavuconazole Administration Other	10 Participants	0 Participants
Number of Participants According to Dosage of Isavuconazole Administration Unknown	5 Participants	0 Participants

SECONDARY outcome

Timeframe: From index date until 6 months after post-index treatment discontinuation, death, or loss to follow-up, whichever occurred first (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Therapeutic Drug Monitoring (TDM)	33 Participants	4 Participants

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Treatment modification was defined as change in dose or dosing schedule of participants who received isavuconazole. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Isavuconazole Treatment Modification	24 Participants	2 Participants

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.

Number of participants with type of treatment modifications required during the index period were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=24 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=2 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Types of Isavuconazole Treatment Modification Change from infusion to oral capsule	13 Participants	1 Participants
Number of Participants With Types of Isavuconazole Treatment Modification Frequency decrease	15 Participants	0 Participants
Number of Participants With Types of Isavuconazole Treatment Modification Other	14 Participants	1 Participants
Number of Participants With Types of Isavuconazole Treatment Modification Dose increase	11 Participants	0 Participants
Number of Participants With Types of Isavuconazole Treatment Modification Dose decrease	6 Participants	1 Participants
Number of Participants With Types of Isavuconazole Treatment Modification Change from oral capsule to infusion	4 Participants	0 Participants
Number of Participants With Types of Isavuconazole Treatment Modification Frequency increase	4 Participants	0 Participants

SECONDARY outcome

Duration between Isavuconazole treatment and treatment modification was defined as the date of first modification minus the date of isavuconazole treatment initiation. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=23 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=2 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Duration Between Isavuconazole Treatment and Treatment Modification	38.6 Days Standard Deviation 59.4	21.5 Days Standard Deviation 27.6

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Percentage of participants who discontinued Isavuconazole treatment were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Percentage of Participants Who Discontinued Isavuconazole Treatment	93.0 Percentage of Participants	94.1 Percentage of Participants

SECONDARY outcome

Duration between Isavuconazole treatment was defined as the date of discontinuation minus the date of isavuconazole treatment initiation. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=187 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=16 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Duration of Isavuconazole Treatment	74.4 Days Standard Deviation 121.7	115.6 Days Standard Deviation 97.5

SECONDARY outcome

Number of participants with reasons for Isavuconazole treatment discontinuation were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=187 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=16 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Participant completed planned course of treatment	40 Participants	8 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Treatment success (resolution of invasive fungal infection)	33 Participants	1 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Other	17 Participants	1 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Lack of response to treatment	12 Participants	1 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Unknown	9 Participants	1 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Adverse event	7 Participants	2 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Participant decision (unrelated to AEs)	3 Participants	0 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Drug-drug interaction	3 Participants	0 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Therapeutic drug monitoring	1 Participants	0 Participants
Number of Participants With Reasons for Isavuconazole Treatment Discontinuation Death (unrelated to therapy)	75 Participants	2 Participants

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants who switched to new antifungal therapy after discontinuation of Isavuconazole were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants Who Switched to New Antifungal	34 Participants	2 Participants

SECONDARY outcome

Number of participants according to new antifungal therapy after end of isavuconazole treatment were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=34 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=2 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Type of New Antifungal Therapy Liposomal amphotericin B	10 Participants	1 Participants
Number of Participants With Type of New Antifungal Therapy Voriconazole	6 Participants	0 Participants
Number of Participants With Type of New Antifungal Therapy Caspofungin	1 Participants	0 Participants
Number of Participants With Type of New Antifungal Therapy Posaconazole	12 Participants	1 Participants
Number of Participants With Type of New Antifungal Therapy Other	5 Participants	0 Participants

SECONDARY outcome

Number of participants with index treatment administered as part of antifungal combination therapy were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019. one participant could have received more than one treatment

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=254 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=44 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Isavuconazole Administered as Part of Combination Therapy	53 Participants	27 Participants

SECONDARY outcome

Concomitant treatments included: Antibiotic agent, corticosteroid agent, chemotherapy, immunosuppressant agent, other and unknown were reported in this outcome measure. One participant could have more than one treatment. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=254 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=44 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants Who Received Other Concomitant Treatments Corticosteroid agent	17 Participants	2 Participants
Number of Participants Who Received Other Concomitant Treatments Chemotherapy	7 Participants	2 Participants
Number of Participants Who Received Other Concomitant Treatments Antibiotic agent	109 Participants	16 Participants
Number of Participants Who Received Other Concomitant Treatments Immunosuppressant agent	3 Participants	1 Participants
Number of Participants Who Received Other Concomitant Treatments Other	5 Participants	3 Participants
Number of Participants Who Received Other Concomitant Treatments Unknown	2 Participants	0 Participants

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants with any outpatient visit (Health Care Professional Visit or Referral) were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Any Outpatient Visits	87 Participants	9 Participants

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Total number of outpatient visit (Health Care Professional Visit or Referral) were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Total Number of Outpatient Visits	103 Outpatient visits	12 Outpatient visits

SECONDARY outcome

Type of outpatient visit (Health Care Professional Visit or Referral) such as secondary care visit (specialist), secondary care referral (specialist), primary care visit (general practitioner) and emergency room (ER) visit were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=87 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=9 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Type of Outpatient Visits Secondary care visit (specialist)	70 Participants	9 Participants
Type of Outpatient Visits Secondary care referral (specialist)	15 Participants	1 Participants
Type of Outpatient Visits Primary care visit (general practitioner)	6 Participants	0 Participants
Type of Outpatient Visits ER visit	4 Participants	1 Participants

SECONDARY outcome

Duration between Isavuconazole treatment was defined as the date of first outpatient visit minus the date of isavuconazole treatment initiation. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=85 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=8 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Duration Between Isavuconazole Treatment Initiation and First Outpatient Visit	63.0 Days Standard Deviation 78.2	82.6 Days Standard Deviation 128.0

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants according to index treatment administered in the inpatient setting were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Inpatient Hospitalization	114 Participants	14 Participants

SECONDARY outcome

Number of participants with primary reason for inpatient hospitalization such as other disease monitoring, other, invasive aspergillosis or mucormycosis disease monitoring, AE related to invasive aspergillosis or mucormycosis and unknown were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=114 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=14 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants With Primary Reason For Inpatient Hospitalization Other disease monitoring	83 Participants	8 Participants
Number of Participants With Primary Reason For Inpatient Hospitalization Unknown	2 Participants	0 Participants
Number of Participants With Primary Reason For Inpatient Hospitalization Other	31 Participants	6 Participants
Number of Participants With Primary Reason For Inpatient Hospitalization Invasive aspergillosis or mucormycosis disease monitoring	27 Participants	2 Participants
Number of Participants With Primary Reason For Inpatient Hospitalization AE related to invasive aspergillosis or mucormycosis	2 Participants	0 Participants

SECONDARY outcome

Duration between Isavuconazole treatment was defined as the date of inpatient hospitalization minus the date of isavuconazole treatment initiation. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=113 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=13 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Duration Between Isavuconazole Treatment Initiation and Inpatient Hospitalization	65.2 Days Standard Deviation 108.8	77.2 Days Standard Deviation 125.1

SECONDARY outcome

Length of stay was computed as the date of discharge from hospital minus the date of hospitalization plus (+) 1. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=113 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=13 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Mean Length of Stay For Inpatient Hospitalization	20.8 Days Standard Deviation 44.3	20.0 Days Standard Deviation 23.7

SECONDARY outcome

Population: Analysis population included all eligible participants whose data was retrieved and analyzed in this study.

Number of participants according to location for inpatient hospitalization such as: hematology ward, other ward, intensive care unit, transplantation ward, emergency room, general medicine ward, oncology ward and unknown were reported in this outcome measure. Index date was defined as date of Isavuconazole treatment initiation anytime in between 15 October 2015 until 30 June 2019.

Outcome measures

Outcome measures
Measure	Invasive Aspergillosis n=201 Participants Participants with aspergillosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.	Mucormycosis n=17 Participants Participants with mucormycosis who received isavuconazole treatment in between 15-Oct-2015 to 30-Jun-2019 under routine clinical practice and whose data were observed in the study, were included in this reporting group.
Number of Participants According to Location for Inpatient Hospitalization Other ward	40 Participants	5 Participants
Number of Participants According to Location for Inpatient Hospitalization Transplantation ward	14 Participants	1 Participants
Number of Participants According to Location for Inpatient Hospitalization Emergency room (ER)	9 Participants	3 Participants
Number of Participants According to Location for Inpatient Hospitalization General medicine ward	9 Participants	0 Participants
Number of Participants According to Location for Inpatient Hospitalization Oncology ward	6 Participants	2 Participants
Number of Participants According to Location for Inpatient Hospitalization Unknown	2 Participants	0 Participants
Number of Participants According to Location for Inpatient Hospitalization Haematology ward	61 Participants	6 Participants
Number of Participants According to Location for Inpatient Hospitalization Intensive unit care (ICU)	21 Participants	1 Participants

Adverse Events

Invasive Aspergillosis

Serious events: 34 serious events

Other events: 17 other events

Deaths: 127 deaths

Mucormycosis

Serious events: 3 serious events

Other events: 2 other events

Deaths: 10 deaths

Serious adverse events

Other adverse events

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER